Non-Stimulant ADHD Medications: Every Option Explained

If someone told you that non-stimulant medications are the backup plan for ADHD, they were wrong. That framing has done real damage. It makes people feel like they are settling for a lesser option when their prescriber suggests atomoxetine or guanfacine, and it keeps people from giving these medications a fair shot.

The reality is more nuanced. Stimulants are first-line for most adults with ADHD because they work fast and the average effect sizes are strong. But about 30% of people with ADHD either cannot tolerate stimulants or do not respond adequately to them (Cortese et al., 2018). That is not a small number. And even among the 70% who do respond, some develop problems over time: cardiovascular concerns, anxiety that worsens on stimulants, sleep disruption that never resolves, or appetite suppression that becomes medically concerning.

Non-stimulants are different tools built for different situations. Some work through mechanisms that stimulants do not touch at all. Others address comorbidities that stimulants make worse. This article covers every FDA-approved non-stimulant for ADHD, plus the most commonly used off-label option, with enough detail to have an informed conversation with your prescriber about which one, if any, makes sense for your situation.

Why prescribers reach for non-stimulants

Understanding when non-stimulants make clinical sense helps you evaluate whether your prescriber's recommendation is reasonable. Here are the most common scenarios.

Substance use history. Stimulants are Schedule II controlled substances with misuse potential. If you have a current or past substance use disorder, many prescribers prefer non-stimulants because none of the options in this article are controlled substances. This does not mean people with SUD cannot ever take stimulants, but non-stimulants remove that variable from the equation.

Cardiovascular concerns. Stimulants increase heart rate and blood pressure. For people with pre-existing hypertension, arrhythmias, or structural heart conditions, non-stimulants can be a safer path. Guanfacine and clonidine actually lower blood pressure, which can be an advantage in some cases.

Comorbid anxiety. Roughly 25% to 50% of adults with ADHD also have a clinically significant anxiety disorder. Stimulants can worsen anxiety symptoms in some people, creating a cycle where you treat the ADHD but amplify the anxiety. Atomoxetine and viloxazine have data showing they can improve both ADHD and anxiety simultaneously. More on this in our article on ADHD medication and anxiety together.

Tic disorders. Stimulants can sometimes trigger or worsen tics. Guanfacine and clonidine are often preferred when ADHD co-occurs with a tic disorder, because these medications can actually reduce tics while treating ADHD symptoms.

Patient preference. Some people simply do not want to take a controlled substance. They may have philosophical objections, workplace restrictions (certain military, aviation, and commercial driving roles prohibit Schedule II medications), or practical frustrations with the monthly prescription dance that stimulants require. Non-stimulants can be prescribed with refills and filled through mail-order pharmacies in most states.

Stimulant failure or intolerance. If you have tried two or more stimulants at adequate doses and either did not respond or could not tolerate the side effects, switching classes is standard practice. About 40% of stimulant non-responders show meaningful improvement on atomoxetine (Newcorn et al., 2008).

Need for 24-hour coverage. Stimulants wear off. Even extended-release formulations have a limited duration, and many people struggle with rebound symptoms in the evening. Non-stimulants provide steady, around-the-clock coverage because they change baseline neurotransmitter levels rather than producing peaks and valleys.

Head-to-head comparison

Before diving into each medication individually, here is a side-by-side look at all five non-stimulant options. This table is simplified. Individual responses vary, and your prescriber will consider factors that a table cannot capture. But it gives you a starting framework.

Atomoxetine (Strattera)

Atomoxetine is the most studied non-stimulant for ADHD and was the first one to receive FDA approval, back in 2002. It works by selectively blocking the norepinephrine transporter (NET). In the prefrontal cortex, the brain region most associated with ADHD-related executive dysfunction, this transporter also clears dopamine. So blocking it effectively increases both norepinephrine and dopamine in the PFC without affecting the reward centers that give stimulants their abuse potential (Bymaster et al., 2002).

The main things to know about atomoxetine:

• Takes 4 to 8 weeks for full effect, with some people improving for up to 24 weeks
• Provides true 24-hour coverage with no peaks, valleys, or rebound
• Metabolized by the CYP2D6 liver enzyme, which varies dramatically between people based on genetics. About 7% of Caucasians are "poor metabolizers" who need significantly lower doses
• Has good evidence for improving both ADHD and comorbid anxiety
• Generic has been available since 2017, making it affordable ($30 to $80 per month without insurance)
• Not a controlled substance, so it can be prescribed with refills

Common side effects include nausea (especially in the first few weeks), decreased appetite, dry mouth, and fatigue. Taking it with food and starting at a low dose helps considerably. Some people find that switching to bedtime dosing turns the drowsiness side effect into a sleep benefit.

We have a full deep-dive on atomoxetine covering the week-by-week timeline, CYP2D6 genetics, dosing strategies, and combination therapy. Read the complete guide: Strattera (Atomoxetine) for ADHD.

Viloxazine (Qelbree)

Viloxazine is the newest FDA-approved non-stimulant for ADHD, and it is the option most people know the least about. It received FDA approval for children and adolescents aged 6 to 17 in April 2021, and for adults in April 2022. If you are reading this and have never heard of it, you are not alone. It is still relatively new in the treatment landscape, and many prescribers are only beginning to gain experience with it.

Here is what makes viloxazine interesting. It is technically classified as a norepinephrine reuptake inhibitor, similar to atomoxetine. But it also has significant serotonin modulating activity, which sets it apart. Specifically, it acts as a 5-HT2B receptor agonist, a 5-HT2C receptor antagonist, and a 5-HT7 receptor antagonist (Yu et al., 2020). In plain language: it affects both norepinephrine and serotonin systems, while atomoxetine is essentially norepinephrine-only.

That dual activity matters clinically. The serotonin modulation may explain why some clinicians are seeing benefits for mood and anxiety symptoms alongside the ADHD improvement. It is not an SSRI or SNRI by classification, but it has serotonergic properties that atomoxetine lacks.

The clinical trial data

In the pivotal adult trial, viloxazine 400mg and 600mg both showed statistically significant improvement compared to placebo on the Adult ADHD Investigator Symptom Rating Scale (AISRS). The 600mg dose showed improvement as early as week 1 in some analyses, which is notably fast for a non-stimulant. By week 6, the response rates (defined as 30% or greater improvement) were significantly higher than placebo.

In pediatric trials, viloxazine showed significant improvement versus placebo in both the 6 to 11 age group and the 12 to 17 age group. Effect sizes were generally in the moderate range, roughly comparable to what is seen with atomoxetine.

What makes it different from Strattera

The two medications are related but distinct. Both block norepinephrine reuptake, but viloxazine's serotonin activity is the key differentiator. This may make viloxazine a better fit for people with comorbid mood or anxiety symptoms, though head-to-head studies comparing the two are limited.

The other practical difference is onset. While atomoxetine typically needs 4 to 8 weeks for full effect, some data suggests viloxazine may start showing benefits within 1 to 2 weeks. This is not a guarantee. Some people still need several weeks. But the possibility of faster onset is a meaningful differentiator for patients who are already skeptical about the slow timeline of non-stimulants.

Side effects

The most common side effects in clinical trials were nausea, drowsiness, headache, and decreased appetite. The side effect profile is broadly similar to atomoxetine, though individual tolerability varies. Nausea was the most common reason for discontinuation in trials.

The cost problem

As of this writing, viloxazine (Qelbree) is available only as a brand-name medication. There is no generic. That means out-of-pocket costs can be significant, often $300 to $400 or more per month without insurance. The manufacturer offers savings programs that can reduce this, and some insurance plans cover it, but cost is a real barrier for many people. If your prescriber recommends viloxazine and cost is a concern, ask about patient assistance programs or check whether your insurance formulary covers it before filling the prescription.

Once-daily dosing makes it convenient. It comes in extended-release capsules that can be opened and sprinkled on applesauce for people who have difficulty swallowing capsules, which is a small practical advantage that some other options do not offer.

Guanfacine extended-release (Intuniv)

Guanfacine works through a completely different mechanism than the NRI medications above. It is a selective alpha-2A adrenergic agonist, which means it activates a specific type of norepinephrine receptor (alpha-2A) in the prefrontal cortex. This strengthens prefrontal cortex signaling directly, improving the brain's ability to regulate attention, behavior, and emotion through a pathway that neither stimulants nor NRIs directly target (Arnsten, 2010).

If you have ever heard that guanfacine is "just a blood pressure medication," that is technically true but misleading. Guanfacine was originally developed for hypertension in the 1980s. But the extended-release formulation (Intuniv) was specifically developed and approved for ADHD in children aged 6 to 17 in 2009. The extended-release version provides smoother, more consistent drug levels than the immediate-release version (Tenex), which matters for ADHD treatment.

Who it works best for

Guanfacine has a particular strength profile. It tends to be most effective for:

• Hyperactivity and impulsivity. If these are your dominant symptoms, guanfacine may help more than NRIs do. It targets the neural circuits involved in behavioral regulation more directly.
• Emotional reactivity. The "short fuse" that many people with ADHD experience, where small frustrations trigger disproportionate emotional responses, often improves with guanfacine. This is sometimes called emotional dysregulation, and it is one of the most impairing but least discussed aspects of ADHD.
• Tic disorders. When ADHD co-occurs with Tourette syndrome or other tic disorders, guanfacine is often preferred because it can reduce tics while treating ADHD. Stimulants, by contrast, can sometimes worsen tics.

Where guanfacine is less effective: pure inattention without significant hyperactivity or impulsivity. If your main problem is zoning out, losing track of conversations, and struggling with working memory, guanfacine alone may not be enough. NRIs or stimulants tend to address inattention more directly.

A powerful add-on

One of guanfacine's most important roles is as an add-on to stimulant medication. This combination is well-studied and commonly used in clinical practice. The idea is that guanfacine addresses the symptoms that stimulants do not fully cover (emotional reactivity, evening/nighttime symptom control, sleep difficulties) while the stimulant handles daytime attention and focus. Studies have shown that the guanfacine-plus-stimulant combination produces greater improvement than either medication alone.

Side effects

Sedation is the big one. Guanfacine can cause significant drowsiness, particularly during the first 2 to 4 weeks and after dose increases. This is not subtle drowsiness for some people. It can feel like being heavily sedated. The standard approach is to start at a low dose and increase gradually, and to take the dose at bedtime so the peak sedation occurs during sleep. For many people, the sedation decreases substantially after a few weeks as the body adjusts.

Low blood pressure is the other significant side effect. Because guanfacine was originally a blood pressure medication, it lowers blood pressure. This can cause dizziness, lightheadedness, or feeling faint when standing up quickly (orthostatic hypotension). For people with already-low blood pressure, this can be limiting.

Headache and stomach pain are also reported, usually mild.

The critical safety note

You cannot stop guanfacine abruptly. Because it lowers blood pressure, stopping suddenly can cause rebound hypertension, which is a dangerous spike in blood pressure. If you need to stop taking guanfacine, your prescriber will taper the dose gradually. This is not optional. Make sure you have enough medication to avoid running out unexpectedly, and never skip multiple doses without talking to your prescriber first.

In adults, guanfacine is used off-label for ADHD since the FDA approval is only for children 6 to 17. However, off-label use is common and supported by clinical evidence. Many adult ADHD specialists prescribe it regularly, particularly as add-on therapy.

Clonidine extended-release (Kapvay)

Clonidine is guanfacine's older cousin. It is also an alpha-2 adrenergic agonist, also originally a blood pressure medication, and also FDA-approved for ADHD in children aged 6 to 17. The extended-release formulation (Kapvay) received ADHD approval in 2010.

The key difference from guanfacine is selectivity. Guanfacine is selective for the alpha-2A receptor subtype, which is the one concentrated in the prefrontal cortex and most relevant to ADHD. Clonidine is less selective, meaning it activates multiple alpha-2 receptor subtypes. The practical consequence: clonidine tends to be more sedating than guanfacine and has a broader side effect profile.

When clonidine makes sense

Clonidine is less commonly prescribed as a standalone ADHD treatment than guanfacine. Its main roles are:

• ADHD with significant sleep problems. Because clonidine is more sedating than guanfacine, some prescribers deliberately use that sedation to help with the insomnia that plagues many people with ADHD. A bedtime dose of clonidine can help with both sleep onset and nighttime restlessness. This is probably its most common use in ADHD treatment.
• Add-on therapy. Like guanfacine, clonidine is used alongside stimulants to address symptoms the stimulant does not fully cover. It is particularly useful when the stimulant causes insomnia, because the clonidine helps with sleep while providing some additional ADHD benefit.
• Hyperactivity and impulsivity in younger children. In very young children where the sedating effects are less problematic (because they can nap), clonidine can help manage hyperactive and impulsive behavior.

Clonidine shares the same critical safety concern as guanfacine: it must be tapered, not stopped abruptly, due to the risk of rebound hypertension. This is actually more of a concern with clonidine than guanfacine because clonidine has stronger blood pressure effects.

Side effects include sedation (often significant), dry mouth, constipation, dizziness, and low blood pressure. The sedation is more pronounced than with guanfacine and may persist longer rather than resolving with time.

For most adults with ADHD, guanfacine is generally preferred over clonidine because of its better selectivity and more favorable side effect profile. Clonidine's main advantage is when the sedation is actually desired for sleep management.

Bupropion (Wellbutrin)

Bupropion occupies an unusual place in ADHD treatment. It is not FDA-approved for ADHD. It is an antidepressant (approved for major depressive disorder and seasonal affective disorder) and a smoking cessation aid (marketed as Zyban for that indication). Its use in ADHD is entirely off-label.

That said, it is one of the most frequently prescribed off-label medications for ADHD, and there are legitimate reasons for that. Bupropion inhibits the reuptake of both dopamine and norepinephrine (DNRI), which are the same two neurotransmitters targeted by stimulants. The mechanism is weaker than stimulants, but it is there, and it provides some degree of ADHD symptom improvement for many people.

When bupropion makes sense

The strongest case for bupropion in ADHD is when depression is in the picture. If you have both ADHD and major depression, bupropion can address both with a single medication. This reduces polypharmacy and simplifies treatment. Many prescribers start here when the two conditions coexist, particularly if the depression is the more impairing condition.

Other situations where bupropion gets considered:

• Stimulant intolerance or non-response, combined with failure of FDA-approved non-stimulants
• Patients who are also trying to quit smoking (bupropion has an additional indication for this)
• Cost sensitivity. Generic bupropion is widely available and inexpensive, often under $20 per month
• Patients who want a non-controlled medication with some dopaminergic activity

The evidence reality check

The evidence base for bupropion in ADHD is weaker than for FDA-approved options. The studies that exist are smaller and fewer, and effect sizes tend to be modest. A meta-analysis by Verbeeck et al. (2017) found bupropion was superior to placebo for adult ADHD, but the evidence quality was lower than for atomoxetine or stimulants. In practical terms, bupropion helps some people with ADHD, but it is less reliably effective than the FDA-approved alternatives.

If you are trying bupropion for ADHD and it is not working after an adequate trial (typically 4 to 6 weeks at therapeutic dose), that does not mean non-stimulants do not work for you. It means one specific non-stimulant did not work, and an FDA-approved option like atomoxetine or viloxazine may produce a different result.

Key risks

Seizure threshold. Bupropion lowers the seizure threshold in a dose-dependent manner. It is contraindicated in people with a seizure disorder, current or past eating disorder (specifically bulimia and anorexia nervosa, because the electrolyte abnormalities these conditions cause further increase seizure risk), or in people undergoing abrupt withdrawal from alcohol or benzodiazepines. The seizure risk at standard doses (300mg per day or less) is low, roughly 0.1%, but it increases at higher doses. This is the main safety concern that distinguishes bupropion from other non-stimulants.

Not a controlled substance. Like the other non-stimulants in this article, bupropion has no DEA schedule and no misuse potential. It can be prescribed with refills and filled through mail-order pharmacies.

Bupropion comes in immediate-release, sustained-release (SR), and extended-release (XL) formulations. For ADHD, the XL formulation (once daily dosing) is most commonly used. The SR and immediate-release versions require multiple daily doses and may not provide as consistent coverage.

Combination strategies

One thing that most ADHD medication guides leave out: combination therapy is common in clinical practice, and sometimes it is the key to getting adequate symptom control. Roughly 25% to 30% of adults with ADHD in specialty care end up on some form of combination treatment. This is not a sign that something went wrong. It reflects the complexity of the condition.

Guanfacine + stimulant

This is the most studied non-stimulant/stimulant combination. The rationale is complementary coverage: the stimulant handles attention and focus during peak hours, while guanfacine smooths out emotional reactivity, helps with evening symptoms, and may improve sleep. Multiple studies have shown this combination is more effective than either medication alone, and it is included in clinical guidelines.

The practical benefit: it often allows for a lower stimulant dose, which reduces stimulant side effects while maintaining or improving overall symptom control.

Atomoxetine + low-dose stimulant

This combination provides a 24-hour norepinephrine "floor" from the atomoxetine, with additional dopaminergic peak-hour coverage from a low-dose stimulant. The atomoxetine handles baseline functioning (morning routine, evening executive function, overnight emotional regulation) while the stimulant adds focus for work or school hours.

Some people who could not tolerate high-dose stimulants do well on this combination because the atomoxetine base allows for a much lower stimulant dose.

When combinations make sense

Your prescriber might consider combination therapy when:

• You have a partial response to one medication class. You are better but not where you need to be.
• You need 24-hour coverage but stimulants wear off too early and dose increases cause side effects
• Specific comorbidities (anxiety, tics, emotional dysregulation) need targeted management alongside core ADHD treatment
• Sleep disruption from stimulants is impairing your functioning. Adding guanfacine or clonidine at bedtime can address this directly.

Combinations should always be managed by your prescriber, with each medication introduced and dose-adjusted separately. Starting two new medications at the same time makes it impossible to tell which one is helping and which one is causing side effects.

How to choose: a simplified framework

Individual responses to medication are highly variable, and the only way to truly know how you will respond to a specific medication is to try it under medical supervision. That said, certain patterns in the research can help guide initial decisions. This framework is deliberately simplified. Your prescriber will consider additional factors specific to your situation.

Main anxiety alongside your ADHD? Consider atomoxetine or viloxazine. Both have data supporting dual benefit for ADHD and anxiety. Atomoxetine has a longer track record. Viloxazine's serotonin activity may provide additional mood benefits.

Mainly hyperactive, impulsive, or emotionally reactive? Consider guanfacine. It targets these symptoms more directly than NRIs do, and it is particularly effective for emotional dysregulation.

ADHD plus depression? Consider bupropion. It is the only non-stimulant that also treats depression as a primary indication. If the depression is the more impairing condition, this may be a logical starting point.

Need the fastest possible onset? Viloxazine may have an edge, with some data showing improvement within 1 to 2 weeks. Guanfacine and clonidine can also show initial effects relatively quickly. Atomoxetine is typically the slowest to reach full effect.

Cost is a major concern? Generic atomoxetine and generic bupropion are both widely available and affordable. Viloxazine (Qelbree) is brand-name only and expensive. Generic guanfacine is available and moderately priced.

Tic disorder present? Guanfacine or clonidine. Both can reduce tics while treating ADHD. This is one of the clearest indication-based choices in ADHD pharmacology.

Sleep is the main secondary problem? Clonidine at bedtime, often as an add-on to daytime ADHD treatment. Its sedating properties become a feature rather than a bug.

Remember: this framework describes population-level trends. You are not a population. If your prescriber recommends something that does not match these patterns, it may be because they are weighing factors specific to you that a general framework cannot capture. Ask them to explain their reasoning.

What to expect when starting any non-stimulant

Regardless of which non-stimulant you try, a few principles apply across the board:

Allow adequate trial time. This is the single most important thing to understand. Non-stimulants are not stimulants. They do not work in an hour. Most need weeks to reach full effect. Quitting after 5 days because "it is not doing anything" is the most common mistake, and it can lead you to rule out a medication that would have worked if given enough time.

Side effects often front-load. Nausea, fatigue, drowsiness, and mood changes are common in the first 1 to 2 weeks and typically decrease over time. Starting at a low dose and increasing gradually helps. Taking medication with food reduces GI side effects for most options. If side effects are intolerable, talk to your prescriber about a slower titration rather than stopping altogether.

Track your symptoms. Because the effects are gradual, it is easy to miss improvement. You might not have a dramatic "the lights turned on" moment. Instead, you might realize after three weeks that you have been finishing tasks more consistently, or that you have not had an emotional blowup in a while. A simple daily rating of your focus, impulsivity, and emotional regulation gives you data to evaluate the medication objectively. UpOrbit can serve as a daily check-in point for tracking how you are doing.

Pair with behavioral strategies. Non-stimulants typically produce moderate symptom improvement. They are unlikely to eliminate your ADHD symptoms entirely. Pairing them with environmental design, task management systems, and understanding how your medication works maximizes the benefit. Medication creates a neurochemical foundation. What you build on that foundation matters.

Food interactions vary by medication. Taking atomoxetine and viloxazine with food reduces nausea. Guanfacine should not be taken with high-fat meals because fat increases absorption and can intensify side effects. For detailed guidance, see our article on ADHD medication and food interactions.

Frequently asked questions

What is the best non-stimulant medication for ADHD?

There is no single best non-stimulant for everyone. Atomoxetine (Strattera) has the most research behind it and is often tried first. Viloxazine (Qelbree) is the newest option and may work faster. Guanfacine (Intuniv) is particularly effective for hyperactivity and impulsivity. Bupropion (Wellbutrin) is useful when ADHD and depression co-occur. The best choice depends on your specific symptoms, comorbidities, and how your body responds individually. Work with your prescriber to match the medication to your clinical picture.

How long do non-stimulant ADHD medications take to work?

Most non-stimulants take 4 to 8 weeks to reach full effect, which is much slower than stimulants that work within hours. Viloxazine (Qelbree) may show improvement within 1 to 2 weeks in some people. Guanfacine and clonidine can show initial effects within 1 to 2 weeks but take longer for full benefit. Atomoxetine typically needs 4 to 8 weeks, with some people continuing to improve for up to 24 weeks. The most common mistake is stopping too early.

Can you take a non-stimulant and stimulant together for ADHD?

Yes, and it is more common than most people realize. The most studied combination is guanfacine plus a stimulant. Atomoxetine plus a low-dose stimulant is also used to provide 24-hour base coverage with additional peak-hour benefit. These combinations can be more effective than either medication alone and may allow for lower doses of each, reducing side effects. They should only be managed by a prescriber who can monitor for interactions and adjust doses carefully.

Is Wellbutrin FDA-approved for ADHD?

No. Bupropion (Wellbutrin) is FDA-approved for major depressive disorder, seasonal affective disorder, and smoking cessation. Its use for ADHD is off-label. Prescribers can legally prescribe it for ADHD based on clinical judgment, but it has not gone through the formal FDA approval process for that indication. The evidence base for bupropion in ADHD is weaker than for FDA-approved options like atomoxetine or viloxazine.

What is the newest non-stimulant ADHD medication?

Viloxazine extended-release (brand name Qelbree) is the newest FDA-approved non-stimulant for ADHD. It was approved for children and adolescents in 2021 and for adults in 2022. It works primarily as a norepinephrine reuptake inhibitor with additional serotonin modulating activity, which distinguishes it from the older non-stimulant atomoxetine. It is currently available as brand-name only, with no generic option.

Do non-stimulant ADHD medications cause weight loss?

Some non-stimulants can cause decreased appetite, particularly atomoxetine and viloxazine, but the effect is generally milder than what stimulants produce. Bupropion is sometimes associated with modest weight loss. Guanfacine and clonidine do not typically cause weight loss and may occasionally cause slight weight gain. Overall, non-stimulants are less likely to cause significant weight changes than stimulant medications. If weight is a concern in either direction, discuss it with your prescriber when choosing a medication.

References

• Bymaster et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex. Neuropsychopharmacology, 27(5).
• Newcorn et al. (2008). Atomoxetine and osmotically released methylphenidate for ADHD. J Clin Psychiatry.
• Arnsten (2010). The use of alpha-2A adrenergic agonists for the treatment of ADHD. Expert Review of Neurotherapeutics, 10(10).
• Verbeeck et al. (2017). Bupropion for ADHD: a systematic review and meta-analysis. CNS & Neurological Disorders Drug Targets.
• Cortese et al. (2018). Comparative efficacy and tolerability of medications for ADHD. The Lancet Psychiatry, 5(9).
• Yu et al. (2020). Viloxazine: pharmacological profile and clinical implications for ADHD. J Clin Psychopharmacology.
• Faraone et al. (2021). World Federation of ADHD Consensus Statement. Neuroscience & Biobehavioral Reviews, 128.